Ai‐Min Hui
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
-
- Protein Degradation and Inhibitors 18
- Ubiquitin and proteasome pathways 14
- Hematology 30
- Multiple Myeloma Research and Treatments 24
- Co-authors
- Masatoshi Makuuchi (13 shared papers)Tadatoshi Takayama (14 shared papers)Xin Li (6 shared papers)Neeraj Gupta (21 shared papers)Yae Kanai (4 shared papers)Michiie Sakamoto (4 shared papers)Nitika Nitika (4 shared papers)Setsuo Hirohashi (3 shared papers)
- Journals
- Blood (14 papers)Journal of Clinical Oncology (14 papers)Hepatology (5 papers)Cancer Letters (2 papers)Life (2 papers)
- Partner nations
- United StatesChinaJapan
In The Last Decade
Ai‐Min Hui
87 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 81
- Hematology 503
- Hepatology 242
- Oncology 574
- Immunology and Allergy 118
- Molecular Biology 1.1k
Countries citing papers authored by Ai‐Min Hui
This map shows the geographic impact of Ai‐Min Hui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ai‐Min Hui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ai‐Min Hui more than expected).
Fields of papers citing papers by Ai‐Min Hui
This network shows the impact of papers produced by Ai‐Min Hui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ai‐Min Hui. The network helps show where Ai‐Min Hui may publish in the future.
Co-authors
The 25 scholars most cited alongside Ai‐Min Hui, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 90 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 238 | |
| 2 | 1996 | 99 | |
| 3 | 2000 | 95 | |
| 4 | 1999 | 90 | |
| 5 | 2004 | 86 | |
| 6 | 1997 | 81 | |
| 7 | 2002 | 70 | |
| 8 | Cell cycle regulators and human hepatocarcinogenesis. | 1999 | 63 |
| 9 | 2008 | 55 | |
| 10 | 2022 | 54 | |
| 11 | 2017 | 54 | |
| 12 | 1999 | 48 | |
| 13 | 2014 | 47 | |
| 14 | 2022 | 45 | |
| 15 | 2016 | 43 | |
| 16 | Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas. | 2000 | 42 |
| 17 | Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. | 2000 | 38 |
| 18 | 2016 | 37 | |
| 19 | 2022 | 34 | |
| 20 | 1999 | 33 |
About Ai‐Min Hui
Ai‐Min Hui is a scholar working on Molecular Biology, Hematology, Oncology, Genetics and Pulmonary and Respiratory Medicine, having authored 90 papers that have together received 2.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (18 papers), Chronic Lymphocytic Leukemia Research (17 papers), Ubiquitin and proteasome pathways (14 papers), Cancer-related Molecular Pathways (14 papers), Peptidase Inhibition and Analysis (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Lung Cancer Treatments and Mutations (6 papers). The work is most often cited by research in Hematology (503 citations), Hepatology (242 citations), Oncology (574 citations), Immunology and Allergy (118 citations) and Molecular Biology (1.1k citations). Ai‐Min Hui has collaborated with scholars based in United States, China and Japan. Frequent co-authors include Masatoshi Makuuchi, Tadatoshi Takayama, Xin Li, Neeraj Gupta, Yae Kanai, Michiie Sakamoto, Nitika Nitika, Setsuo Hirohashi, Karthik Venkatakrishnan and Lin Sun. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hepatology, Cancer Letters and Life.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.